PROCEPT BioRobotics Reports Second Quarter 2025 Financial Results and Increases 2025 Revenue Guidance

Core Viewpoint - PROCEPT BioRobotics Corporation reported a strong financial performance for Q2 2025, with a 48% year-over-year revenue growth, driven by increased demand for its Aquablation therapy and expansion in both U.S. and international markets [3][4]. Financial Performance - Total revenue for Q2 2025 was $79.2 million, a 48% increase compared to Q2 2024 [4][9]. - U.S. revenue reached $69.6 million, reflecting a 46% growth year-over-year, primarily from system sales and increased handpiece revenue [4][9]. - International revenue was $9.6 million, marking a 69% increase compared to the prior year [4][9]. - U.S. handpiece and consumable revenue was $43.1 million, up 58% year-over-year [4][9]. - Gross margin improved to 65% in Q2 2025 from 59% in the prior year, attributed to operational efficiencies and higher selling prices [5]. Operating Expenses and Losses - Operating expenses for Q2 2025 were $73.9 million, up from $58.3 million in Q2 2024, driven by expansion of the commercial organization and increased R&D expenses [6]. - The net loss for Q2 2025 was $19.6 million, an improvement from a loss of $25.6 million in the same period last year [7][9]. - Adjusted EBITDA loss was $8.0 million for Q2 2025, compared to a loss of $17.9 million in Q2 2024 [7][9]. Future Guidance - The company projects full-year 2025 revenue to be approximately $325.5 million, representing a 45% growth over the previous year [8][9]. - Full-year 2025 gross margin is expected to be around 64.5% [15]. - The company anticipates total operating expenses for 2025 to be approximately $302.0 million [15]. Leadership Changes - Larry Wood has been appointed as the new CEO, effective September 2, 2025, bringing 40 years of experience in the medical technology industry [9]. Product and Market Focus - The company is focused on expanding the utilization of Aquablation therapy in the U.S. and enhancing its presence in international markets [3]. - PROCEPT BioRobotics aims to revolutionize BPH treatment globally through its robotic solutions, which are designed to deliver effective outcomes for patients [11].